Lawmakers Ask HHS to Probe the Medicaid Drug Rebate Program

In the wake of the controversy over EpiPen pricing, a group of lawmakers is demanding a probe into the Medicaid Drug Rebate Program, which requires drug makers to pay rebates in exchange for having their products covered.

In a letter sent Tuesday to the Inspector General at the US Department of Health and Human Services, 15 House Republicans want to know the extent to which the Centers for Medicare and Medicaid Services is properly overseeing the program and how medicines are classified. The probe should include, “but not be limited to” EpiPen, Representative Fred Upton (R-Mich.) and the other lawmakers wrote.